Both Hepatocyte Growth Factor (HGF) and Stromal-Derived Factor-1 Regulate the Metastatic Behavior of Human Rhabdomyosarcoma Cells, but only HGF Enhances Their Resistance to Radiochemotherapy

Cancer Research

Volumn 63, Issue 22, 2003, Pages 7926-7935

  Jankowski, Kacper ^a   Kucia, Magda ^a   Wysoczynski, Marcin ^a   Reca, Ryan ^a   Zhao, Dongling ^b   Trzyna, Ela ^c   Trent, John ^a   Peiper, Stephen ^a   Zembala, Marek ^c   Ratajczak, Janina ^a   Houghton, Peter ^d   Janowska Wieczorek, Anna ^b   Ratajczak, Mariusz Z ^a  

^a UNIVERSITY OF LOUISVILLE   (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

^c JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^d ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; SCATTER FACTOR; STROMAL CELL DERIVED FACTOR 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL PROLIFERATION; CONTROLLED STUDY; FIBROBLAST; HUMAN; HUMAN CELL; LOCOMOTION; LUNG ALVEOLUS CELL; MOUSE; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; RHABDOMYOSARCOMA;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ACTINS; BONE MARROW NEOPLASMS; CELL DIVISION; CELL MOVEMENT; CHEMOKINES, CXC; CHEMOTAXIS; CYTOSKELETON; DRUG RESISTANCE, NEOPLASM; ENDOTHELIUM, VASCULAR; HEPATOCYTE GROWTH FACTOR; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MET; RADIATION TOLERANCE; RECEPTORS, CXCR4; RHABDOMYOSARCOMA;

EID: 10744231064     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Sharp, R., Recio, J. A., Jhappan, C., Otsuka, T., Liu, S., Yu, Y., Liu, W., Anver, M., Navid, F., Helman, L. J. DePinho, R. A., and Merlino, G. Synergism between INK4a/ARF inactivation and aberrant HGF signaling in rhabdomyosarcomagenesis. Nat. Med., 8: 1276-1280, 2002.
2. Ruymann, F. B., Newton, W. A., Ragab, A. H., Donaldson, M. H., and Foulkes, M. Bone marrow metastases at diagnosis in children and adolescents with rhabdomyosarcoma. Cancer (Phila.), 53: 368-373, 1984.
3. Sandberg, A. A., Stone, J. F., Czarnecki, L., and Cohen, J. D. Hematologic masquerade of rhabdomyosarcoma. Am. J. Hematol., 68: 51-57, 2001.
4. Barr, F. G., Galili, N., Holick, J., Biegel, J. A., Rovera, G., and Emanuel, B. S. Rearrangement of the PAX3 paired box gene in the paediatric solid tumour alveolar rhabdomyosarcoma. Nat. Genet., 3: 113-117, 1993.
5. Hazelton, B. J., Houghton, J. A., Parham, D. M., et al. Characterization of cell lines derived from xenografts of childhood rhabdomyosarcoma. Cancer Res., 47: 4501-4507, 1987.
6. Davis, R. J., and Barr, F. G. Fusion genes resulting from alternative chromosomal translocations are overexpressed by gene-specific mechanisms in alveolar rhabdomyosarcoma. Proc. Natl. Acad. Sci. USA, 94: 8047-8051, 1997.
7. Davis, R. J., D'Cruz, C. M., Lovell, M. A., Biegel, J. A., and Barr, F. G. Fusion of PAX7 to FKHR by the variant t(1;13)(p36;q14) translocation in alveolar rhabdomyosarcoma. Cancer Res., 54: 2869-2872, 1994.
8. Collins, M. H., Zhao, H., Womer, R. B., and Barr, F. G. Proliferative and apoptotic differences between alveolar rhabdomyosarcoma subtypes: a comparative study of tumors containing PAX3-FKHR gene fusions. Med. Pediatr. Oncol., 37: 83-89, 2000.
9. Bennicelli, J. L., Advani, S., Schafer, B. W., and Barr, F. G. PAX3 and PAX7 exhibit conserved cis-acting transcription repression domains and utilize a common gain of function mechanism in alveolar rhabdomyosarcoma. Oncogene, 18: 4348-4356, 1999.
10. Kelly, K. M., Womer, R. B., and Barr, F. 3-FKHR and PAX7-FKHR fusions in rhabdomyosarcoma. J. Pediatr. Hematol. Oncol., 20: 517-518, 1998.
11. Libura, J., Drukala, J., Majka, M., et al. CXCR4-SDF-1 signaling is active in rhabdomyosarcoma cells and regulates locomotion, chemotaxis, and adhesion. Blood, 100: 2597-2606, 2002.
12. Ginsberg, J. P., Davis, R. J., Bennicelli, J. L., Nauta, L. E., and Barr, F. G. Up-regulation of MET but not neural cell adhesion molecule expression by the PAX3-FKHR protein in alveolar rhabdomyosarcoma. Cancer Res., 58: 3542-3546, 1998.
13. Anderson, J., Ramsay, A., Gould, S., Pritchard-Jones K. PAX3-FKHR induces morphological change and enhances cellular proliferation and invasion in rhabdomyosarcoma. Am. J. Pathol., 159: 1089-1096, 2001.
14. Epstein, J. A., Shapiro, D. N., Cheng, J., Lam, P. Y. P., and Maas, R. L. Pax3 modulates expression of the c-Met receptor during limb muscle development. Proc. Natl. Acad. Sci. USA, 93: 4213-4218, 1996.
15. Ferracini, R., Olivero, M. DiRenzo, M. F., Martano, M., DeGiovanni, C., Nanni, P., Basso, G., Scotlandi, K., Lollini, P. L., and Comoglio, P. M. Retrogenic expression of the MET proto-oncogene correlates with the invasive phenotype of human rhabdomyosarcoma. Oncogene, 12: 1697-1705, 1996.
16. Corti, S., Salani, S., Del Bo, R., et al. Chemotactic factors enhance myogenic cell migration across an endothelial monolayer. Exp. Cell Res., 268: 36-44, 2001.
17. Danilkovitch-Miagkova, A., and Zbar, B. Dysregulation of Met receptor tyrosine kinase activity in invasive tumors. J. Clin. Invest., 109: 863-867, 2002.
18. Comoglio, P. M., and Trusolino, L. Invasive growth: from development to metastasis. J. Clin. Invest., 109: 857-862, 2002.
19. Goshima, Y., Ito, T., Sasaki, Y., Nakamura, F. Semaphorins as signals for cell repulsion and invasion. J. Clin. Invest., 109: 993-998, 2002.
20. Mualik, G., Shrikhande, A., Kijima, T., et al. Role of hepatocyte growth factor receptor, c-Met, in oncogenesis and potential therapeutic inhibition. Cytokine Growth Factor Rev., 13: 41-59, 2002.
21. Tamagnone, L., and Comoglio, P. M. Control of invasive growth by hepatocyte growth factor (HGF) and related scatter factors. Cytokine Growth Factor Rev., 8: 129-142, 1997.
22. Zou, Y., Kottmann, A. H., Kuroda, M., Taniuchi, I., and Littman, D. R. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature (Lond.), 393: 595-599, 1998.
23. + progenitors to peripheral blood. J. Exp. Med., 185: 111-120, 1997.
24. + hematopoietic progenitors and leukemic cells and mediates transendothelial migration induced by stromal cell-derived factor-1. Blood, 91: 4523-4530, 1998.
25. + cells on vascular endothelium under shear flow. J. Clin. Invest., 104: 1199-1211, 1997.
26. Wang, J-F., Park, I-W., and Groopman, J. E. Stromal cell-derived factor-1α stimulates tyrosine phosphorylation of multiple focal adhesion proteins and induces migration of hematopoietic progenitor cells: roles of phosphoinositide-3 kinase and protein kinase C. Blood, 95: 2505-2513, 2000.
27. Ratajczak, M. Z., Marlicz, W., Ratajczak, J., Wasik, M., Machalinski, B., Carter, A., and Gewirtz, A. M. Effect of hepatocyte growth factor on early human haemopoietic cell development. Br. J. Haematol., 99: 229-236, 1997.
28. Kijowski, J., Baj, M., Majka, M., et al. The SDF-1-CXCR4 axis stimulates VEGF secretion and activates integrins but does not affect proliferation and survival in lymphohematopoietic cells. Stem Cells, 19: 453-466, 2001.
29. Majka, M., Janowska-Wieczorek, A., Ratajczak, J., et al. Stromal derived factor-1 and thrombopoietin regulate distinct aspects of human megakaryopoiesis. Blood, 96: 4142-4151, 2000.
30. Majka, M., Ratajczak, J., Lee, B., et al. The role of HIV related chemokine receptors and chemokines in human erythropoiesis in vitro. Stem Cells. 18: 128-138, 2000.
31. Majka, M., Janowska-Wieczorek, A., Ratajczak, J., et al. Numerous growth factors, cytokines and chemokines are secreted by human CD34+ cells, myeloblasts, erythroblasts and megakaryoblasts and regulate normal hematopoiesis in an autocrine/paracrine manner. Blood, 97: 3075-3085, 2001.
32. Madeja, Z., Szymkiewicz, I., Zaczek, A., Sroka, J., Miêkus, K., and Korohoda, W. Contact-activated migration of melanoma B16 and sarcoma XC cells. Biochem. Cell Biol., 79: 1-16, 2001.
33. Korohoda, W., and Madeja, Z. Contact of sarcoma cells with aligned fibroblasts accelerates their displacement: computer-assisted analysis of tumour cell locomotion in co-culture. Biochem. Cell Biol., 75: 263-276, 1997.
34. Janowska-Wieczorek, A., Marquez, L. A., Matsuzaki, A., et al. Expression of matrix metalloproteinases (MMP-2 and -9) and tissue inhibitors of metalloproteinases (TIMP-1 and -2) in acute myelogenous leukaemia blasts: comparison with normal bone marrow cells. Br. J. Haematol., 105: 402-411, 1999.
35. Janiak, M., Hashmi, H. R., and Janowska-Wieczorek, A. Use of the Matrigel-based assay to measure the invasiveness of leukemic cells. Exp. Hematol., 22: 559-565, 1994.
36. + cells and their transmigration through reconstituted basement membrane. Blood, 93: 3379-3390, 1999.
37. Livak, K. J., and Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods, 25: 402-408, 2001.
38. Morotti, A., Mila, S., Accornero, P., Tagliabue, E., and Ponzetto, C. K. 252a inhibits the oncogenic properties of Met, the HGF receptor. Oncogene, 21: 4885-4893, 2002.
39. Taichman, R. S., Cooper, C., Keller, E. T., Pienta, K. J., Taichman, N. S., and McCauley, L. K. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res., 62: 1832-1837, 2002.
40. Weigel, B. J., Breitfeld, P. P., Hawkins, D., Crist, W. M., and Baker, K. S. Role of high-dose chemotherapy with hematopoietic stem cell rescue in the treatment of metastatic or recurrent rhabdomyosarcoma. J. Pediatr. Hematol. Oncol., 23: 272-276, 2001.
41. Mueller, A., Homey, B., Soto, H., et al. Involvement of chemokine receptors in breast cancer metastasis. Nature (Lond.), 410: 50-56, 2000.
42. Geminder, H., Sagi-Assif, O., Goldberg, L., et al. A possible role for CXCR4 and its ligand, the CXC chemokine stromal cell-derived factor-1, in the development of bone marrow metastases in neuroblastoma. J. Immunol., 167: 4747-4757, 2001.
43. Bachelder, R. E., Wendt, M. A., and Mercurio, A. M. Vascular endothelial growth factor promotes breast carcinoma invasion in an autocrine manner by regulating the chemokine receptor CXCR4. Cancer Res., 62: 7203-7206, 2002.
44. Scotton, C. J., Wilson, J., Scott, K., Stamp, G., Wilbanks, G. D., Fricker, S., Bridger, G., and Balkwill, R. Multiple action of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. Cancer Res., 62: 5930-5938, 2002.
45. Kijima, T., Maulik, G., Ma, P. C., Tibaldi, E. V., Turner, R. E., Rollins, B., Sattler, M., Johnson, B. E., and Salgia, R. Regulation of cellular proliferation, cytoskeletal function and signal transduction through CXCR4 and c-kit in small cell lung cancer cells. Cancer Res., 62: 6304-6311, 2002.
46. Mayanil, C. S. K., George, D., Freilich, L., Miljan, E. J., Mania-Farnell, B., McLone, D. G., and Bremer, E. G. Microarray analysis detects novel Pax3 downstream target genes. J. Biol. Chem., 276: 49299-49309, 2001.
47. Murphy, P. M. Chemokines and the molecular basis of cancer metastasis. N. Engl. J. Med., 345: 833-835, 2001.
48. Zhang, W. W., Navenot, J. M., Haribabu, B., et al. A point mutation that confers constitutive activity to CXCR4 reveals T140 is an inverse agonist and AMD3100 and ALX40-4C are weak partial agonists. J. Biol. Chem., 277: 24515-24521, 2002.
49. Tamamura, H., Xu, Y., Hattori, T., et al. A low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140. Biochem. Biophys. Res. Commun., 253: 877-882, 1998.
50. Hatse, S., Princen, K., Bridger, G., De Clercq, E., and Schols, D. Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4. FEBS Lett., 527: 255-262, 2002.
51. Webb, C. P., Hose, C. D., Koochekpour, S., et al. The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor Met-urokinase plasminogen activator plasmin proteolytic network. Cancer Res., 60: 342-349, 2000.
52. Bardelli, A., Longati, P., Williams, T. A., et al. A peptide representing the carboxyl-terminal tail of the Met receptor inhibits kinase activity and invasive growth. J. Biol. Chem., 274: 29274-29281, 1999.